Palopegteriparatide Clinical Trials (2026): 4 Studies for Hypoparathyroidism & Endocrine System Diseases
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 Palopegteriparatide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Hypoparathyroidism & Endocrine System Diseases) and 96 total planned enrollment. 1 Phase 3 Palopegteriparatide trial are listed. 3 Palopegteriparatide clinical trials are actively recruiting at 5 U.S. sites across 4 states. Most recent activity: NCT07345494 (Jan 2036).
Where to Participate: All Palopegteriparatide Trial Sites in the U.S. (5 sites across 4 states)
Every actively recruiting Palopegteriparatidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| NV | Ascendis Pharma Investigational Site | Reno89511 | NCT07081997 | Map |
| NY | Ascendis Pharma Investigational Site | New York10032 | NCT07081997 | Map |
| WA | Ascendis Pharma Investigational Site | Spokane Valley99216 | NCT07081997 | Map |
| WV | Ascendis Investigational Site | Morgantown26508 | NCT07264634 | Map |
| WV | Ascendis Investigational Site | Morgantown26508 | NCT07345494 | Map |
Palopegteriparatide clinical trials at a glance: phase × recruitment status
| Phase | recruiting | approved for marketing | Total |
|---|---|---|---|
| P3 | 1 | 1 | |
| N/A | 2 | 1 | 3 |
Recruiting Palopegteriparatide clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07345494 | A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding | — | Hypoparathyroidism | 50 | Feb 2026 |
| NCT07081997 | PaTHway60A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism | P3 | Hypoparathyroidism | 36 | Apr 2026 |
| NCT07264634 | A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) | — | Hypoparathyroidism | 10 | Mar 2026 |
Palopegteriparatide pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| PaTHway60 | NCT07081997 | P3 | recruiting | Hypoparathyroidism | 36 | — |
All Palopegteriparatide trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07345494 | A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding | — | recruiting | 50 | Ascendis Pharma A/S | Feb 2026 | |
| NCT07081997 | PaTHway60 | A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism | P3 | recruiting | 36 | Ascendis Pharma Bone Diseases A/S | Apr 2026 |
| NCT07264634 | A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) | — | recruiting | 10 | Ascendis Pharma A/S | Mar 2026 | |
| NCT05654701 | Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism | — | approved for marketing | 0 | Ascendis Pharma Bone Diseases A/S | — |
Palopegteriparatide clinical trials: frequently asked questions
- How many Palopegteriparatide clinical trials are there?
- 4 Palopegteriparatide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are Palopegteriparatide clinical trials recruiting in 2026?
- Yes — 3 Palopegteriparatide trials are actively recruiting in 2026, with 5 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Palopegteriparatide being studied for?
- Palopegteriparatide is being studied for Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases. The trials are grouped by indication on this page.
- What phase is Palopegteriparatide in?
- Palopegteriparatide clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Palopegteriparatide clinical trials?
- The lead sponsor across the most Palopegteriparatide trials is Ascendis Pharma A/S, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Palopegteriparatideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: